Everolimus: A Guide to Its Use in Liver Transplantation.
BioDrugs. 2013 May 22;
Authors: Keating GM, Lyseng-Williamson KA
Abstract
The mammalian target of rapamycin inhibitor everolimus (Zortress(�), Certican(�)) was recently approved in the USA and a number of EU countries for use in combination with a reduced dosage of tacrolimus and corticosteroids for the prophylaxis of organ rejection in adult liver transplant recipients. Compared with standard-exposure tacrolimus, early use of everolimus plus a reduced dosage of tacrolimus did not compromise efficacy in liver transplant recipients. In addition, significantly better renal function with everolimus plus reduced-exposure tacrolimus than with standard-exposure tacrolimus was seen from 6�weeks post-transplant onwards. Everolimus plus reduced-exposure tacrolimus has an acceptable tolerability profile in liver transplant recipients.
PMID: 23696253 [PubMed - as supplied by publisher]
没有评论:
发表评论